# OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

> **NCT04948307** · NA · COMPLETED · sponsor: **Orexo AB** · enrollment: 437 (actual)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DEVICE:** OXD01 digital therapy
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04948307
- **Lead sponsor:** Orexo AB
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-30
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-05-10
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948307, "OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04948307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*